Clinical Interests

My clinical areas of interest include pediatric inflammatory bowel disease and general pediatric gastrointestinal illness.

Education

  • BS, Highest Distinction and Highest Honors, University of North Carolina at Chapel Hill1998
  • MD, Thesis Honors, University of Washington2003

Training

  • Pediatric Residency, Univeristy of North Carolina at Chapel Hill/NC Children's Hospital2003 - 2006
  • Pediatric Gastroenterology Fellowship, Cincinnati Children's Hospital Medical Center2006 - 2009
  • Advanced Improvement Methods Workshop, Cincinnati Children's Hospital Medical Center2014 - 2015
  • Pediatric Leadership Development Program, Washington University School of Medicine2016 - 2016

Licensure and Board Certification

  • NC, NC Training License 2003
  • OH, Ohio Training Certificate 2006
  • American Board of Pediatrics; General Pediatrics 2006
  • OH, Ohio Medical License 2009
  • American Board of Pediatrics; Pediatric Gastroenterology 2009
  • MO, Missouri Medical License 2011
  • AR, Arkansas Medical License 2016

Honors

  • David L Stern Award; Department of Chemistry; University of North Carolina at Chapel Hill1997
  • Phi Beta Kappa; University of North Carolina at Chapel Hill1997
  • Highest Distinction Graduate; University of North Carolina at Chapel Hill1998
  • Highest Honor's Thesis in Chemistry; University of North Carolina at Chapel Hill1998
  • Venable Medal; Department of Chemistry; University of North Carolina at Chapel Hill1998
  • Medical Thesis Honors; University of Washington School of Medicine2002
  • Fellowship to Facutly Transition Award; Foundation of the American Gastroenterological Association2009
  • Pediatric Loan Repayment Award; National Institutes of Health2009
  • Procter Scholar Award; Cincinnati Children's Hospital Medical Center2009
  • Poster of Distinction, Digestive Disease Week2011

Recent Publications view all (14)


  1. Remission in Pediatric Inflammatory Bowel Disease Correlates with Prescription Refill Adherence Rates. J Pediatr Gastroenterol Nutr. 2016. PMID:27299424 
  2. Improved outcomes with quality improvement interventions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012;55(6):679-88. doi:10.1097/MPG.0b013e318262de16  PMID:22699837 
  3. Budesonide use in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012;55(2):200-4. doi:10.1097/MPG.0b013e31824a09c2  PMID:22258289 
  4. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics. 2012;129(4):e1030-41. doi:10.1542/peds.2011-1700  PMCID:PMC3313634  PMID:22412030 
  5. Granulocyte-macrophage colony stimulating factor blockade promotes ccr9(+) lymphocyte expansion in Nod2 deficient mice. Inflamm Bowel Dis. 2011;17(12):2443-55. doi:10.1002/ibd.21672  PMCID:PMC3111853  PMID:21381154 
  6. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011;106(5):981-7. doi:10.1038/ajg.2010.493  PMID:21224840 
  7. Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series. Inflamm Bowel Dis. 2011;17(1):56-61. doi:10.1002/ibd.21378  PMID:20645322 
  8. Loss of GM-CSF signalling in non-haematopoietic cells increases NSAID ileal injury. Gut. 2010;59(8):1066-78. doi:10.1136/gut.2009.203893  PMID:20584783 
  9. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology. 2009;136(4):1261-71, e1-3. doi:10.1053/j.gastro.2008.12.046  PMID:19230854 
  10. Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism. J Hepatol. 2004;40(6):942-51. doi:10.1016/j.jhep.2004.02.031  PMID:15158334 
  11. TNF alpha-induced hepatocyte apoptosis is associated with alterations of the cell cycle and decreased stem loop binding protein. Surgery. 2004;135(6):619-28. doi:10.1016/j.surg.2003.11.004  PMID:15179368 
  12. Cirrhotic hepatocytes exhibit decreased TGFbeta growth inhibition associated with downregulated Smad protein expression. Biochem Biophys Res Commun. 2004;313(3):546-51. PMID:14697224 
  13. NFkappaB inhibition decreases hepatocyte proliferation but does not alter apoptosis in obstructive jaundice. J Surg Res. 2003;114(2):110-7. PMID:14559434 
  14. Transforming growth factor-beta1 induces hepatocyte apoptosis by a c-Jun independent mechanism. Surgery. 2002;132(3):441-9. PMID:12324757 
Wash U School of Medicine
Children's Hospital St. Louis
Children's Discovery Institute
© 2017 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130